Michael Shurin, MD, PhD
Professor of Pathology

Dr. Shurin
Dr. Shurin is the Director of the Division of Clinical Immunopathology.
Office Location:
S735, Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-648-9841
Lab Telephone: 412-648-9831
Fax: 412-648-8158
Email: shurinmr@upmc.edu

Clinical Expertise

Dr. Shurin's clinical duties include the everyday evaluation of results of numerous blood tests, teaching Pathology residents and medical students, and dealing with different administrative issues at the Division of Clinical Immunopathology. Immunodiagnostic tests include a number of ELISA, RIA, IF, electrophoresis, Western blot tests for autoimmune, infectious, allergic and immunoproliferative diseases.

Research Expertise

Our research program focuses on the mechanisms of cellular and molecular interactions in the tumor microenvironment. Cancer is the result of complex interactions between the malignant cells and the cells that are present in the surrounding environment. The elements of the tumor microenvironment can collectively exert both stimulatory and inhibitory pressures on the proliferative, angiogenic and immunomodulating potential of cancerous cells, as well as their ability to spread and metastasize. Thus, insights into the mechanisms regulating host responses to growing tumors are essential for assessing relative risks and improving the therapeutic index for novel therapies associated with the modulation of the tumor microenvironment. Tumor-mediated immune suppression and tolerance remains a key obstacle to the safe and efficacious induction of antitumor immunity by immunotherapeutic modalities. Myeloid regulatory cells (MRC), a heterogeneous group of cells that accumulate in tumor-bearing hosts, have been proven to play a critical role in tumor growth and spreading, as well as in limiting the efficacy of several cancer treatment programs, including immunotherapy and angiogenic inhibitors. Our long-term goal is to develop a feasible and effective therapeutic approach based on a combination of pharmacological inhibition of specific MRC pathways and recovery/boosting of tumor specific immune responses.

Although an important role of MRC in tumor-associated immune suppression has been established in recent years, the nature of specific MRC populations and the inter-differentiation pathways of MRC remain largely obscure. For instance, despite the fact that cross-talk between myeloid-derived suppressor cells (MDSC) and macrophages and MDSC differentiation into tumor-associated macrophages (TAM) in the tumor environment have been addressed, the relationship between MDSC and recently described suppressor (regulatory) dendritic cells (DC) is unclear. The nature of suppressor DC in cancer, the mechanisms of their polarization and their immunosuppressive function are not well characterized. With the exception of MDSC, clinical approaches to control appearance and differentiation of MRC populations are not defined. The ambiguous nature of the biological roles of, and the relationship between, different myeloid cell subsets within the tumor site limits our understanding of the biology of tumor progression and the development of targeted therapeutics. Our major hypothesis is that the tumor microenvironment differentially controls emergence of specific MRC populations which, however, can be redirected by molecular-targeted therapy to support recovery of the antitumor immunity and improve the efficacy of cancer immunotherapy. Our objectives are to determine the mechanisms of MRC differentiation as directed by specific premalignant and tumor environment and develop MRC molecular-targeted strategies that generate efficient antitumor immunity in vivo. In addition, we initiated studies that address another key question about the development of specific immunological microenvironment in cancer (the tumor immunoenvironment): Modulation of premalignant/malignant microenvironment by environmental agents. Specifically, we investigate how airborne nanomaterials affect the development of lung cancer.


Diplomat, American Board of Medical Laboratory Immunology (ABMLI)


Clinical immunology and Immunopathology

NIH Research

View Dr. Shurin's NIH RePORT on nih.gov

Selected Publications

View Dr. Shurin's publications on PubMed

Peer-Reviewed Articles

  • Shurin M.R., Keskinov A.A. Low-Dose Chemomodulation and Cancer Vaccines. Editorial. J Vaccines Vaccination, 5: e126. doi: 10.4172/2157-7560.1000e126., 2014.
  • Zhong H, Gutkin D.W., Han B., Ma Y., Keskinov A.A., Shurin M.R., Shurin G.V. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Intl J Cancer, 134(11):2633-45, 2014.
  • Shurin M.R., Yanamala N., Kisin, E.R., Tkach A.V., Shurin G.V., Murray A., Leonard H., Reynolds J., Gutkin D.W., Star A., Fadeel B., Savolainen K., Kagan V.E., Shvedova A.A. Graphene Oxide Attenuates Th2-type Immune Responses, but Augments Airway Remodeling and Hyperresponsiveness in a Murine Model of Asthma. ACS Nano, 8(6):5585-99, 2014.
  • Anani W.Q., Ojerholm E.J., Shurin M.R. Resolving Transferrin Isoforms by Agarose Gel Electrophoresis. Lab Medicine, 46(1):26-33, 2015.
  • Shvedova A.A., Tkach A.V., Kisin E.R., Stanley S., Gutkin D.W., Star A., Shurin G.V., Kagan V.E., Shurin M.R. MDSC and TGF-β are required for facilitation of tumor growth in the lungs of mice exposed to carbon nanotubes, Cancer Research, 75(8):1615-23, 2015.
  • Kisin E., Yanamala N., Farcas M., Gutkin D., Shurin M., Kagan V., Bugarski A., Shvedova A. Abnormalities in Male Reproductive System after Exposure to Diesel and Biodiesel Blend. Environmental and Molecular Mutagenesis, 56(2):265-276, 2015.
  • Zhao Y., Burkert S.C., Tang Y., Sorescu D.C., Kapralov A.A., Shurin G.V., Shurin M.R., Kagan V.E., Star A. Nano-Gold Corking and Enzymatic Uncorking of Carbon Nanotube Cups. J Amer Chem Soc., 137(2):675-684, 2015.
  • Seo W., Kapralov A.A., Shurin G.V., Shurin M.R., Kagan V.E., Star A. Payload Drug vs. Nanocarrier Biodegradation by Myeloperoxidase- and Peroxynitrite-Mediated Oxidations: Pharmacokinetic Implications. Nanoscale. 7(19):8689-94, 2015.
  • Landreneau J.P., Shurin M.R., Agassandian M.V., Keskinov A.A., Ma Y., Shurin G.V. Immunological mechanisms of low and ultra-low dose cancer chemotherapy. Cancer Microenvironment, 2014, in press.
  • Shurin M.R., Umansky V., Malyguine A., Hurwitz A., Apte R.N., Whiteside T., Jewett A, Thanavala Y., Murphy W.J. Cellular and Molecular Pathways in the Tumor Immunoenvironment: 3d Cancer immunotherapy and immunomonitoring (CITIM) meeting, Krakow, 22-25 April, 2013. Cancer Immunol. Immunother., 63:7380, 2014.
  • Gutkin D.W., Shurin M.R. Clinical evaluation of systemic and local immune responses in cancer: Time for integration. Cancer Immunol. Immunother., 63:4557, 2014.
  • Shurin M.R., Keskinov A.A., Chatta G. Immunobiology of dendritic cells in cancer. In: Mechanisms of therapeutic reversal of immune suppression in cancer, D.I.Gabrilovich and A. Hurtwiz (Eds), 2nd Edition, Springer, pp. 151-184, 2014.
  • Agassandian M., Shurin G.V., Ma Y., Shurin M.R. C-reactive protein and lung diseases. The Intl J Biochem Cell Biology, 53: 77-88, 2014.
  • Keskinov A.A., Shurin M.R. Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology, 220(2):236-42, 2015.


  • Kotlan B., Umansky V., Malyguine A.M., Marincola F.M., Shurin M.R. Conference Scene: Immunotherapy reaches new milestones in cancer eradication. Immunotherapy, 3(10):1131-1137, 2011.
  • Umansky V., Malyguine A., Kotlan B., Aptsiauri N., Shurin M.R. From cell regulation to patient survival: 2nd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting. Cancer Immunol. Immunother., 61(2): 223230, 2012 (NIHMS 363339).
  • Malyguine A., Umansky V., Kotlan B., Aptsiauri N., Shurin M.R. Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward. J. Immunotoxicol., 9(3):231-235, 2012.
  • Malyguine A., Strobl S., Shurin M.R. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol. Immunother., 61(2):239-47, 2012.
  • Shurin G.V., Ouellette C.E., Shurin M.R. Regulatory dendritic cells in the tumor immuno-environment. Cancer Immunol. Immunother., 61(2):223-30, 2012.
  • Shurin M.R., Naiditch H., Gutkin D.W., Umansky V., Shurin G.V. ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents. Curr. Med. Chem., 19(12):1792-1803, 2012.
  • Ma Y., Shurin G.V., Gutkin D.W., Shurin M.R. Tumor-associated regulatory dendritic cells. Seminars in Cancer Biology, 22(4):298-306, 2012.
  • Malyguine A., Strobl S., Dunham K., Shurin M., Sayers T. ELISPOT assay for monitoring CTL activity in cancer vaccine clinical trials. Cells, 1(2), 111-126, 2012.
  • Ma Y., Shurin G.V., Zhu P., Shurin M.R. Dendritic cells in the cancer microenvironment. Journal of Cancer;4(1):36-44, 2013.
  • Malyguine A., Umansky V., Shurin M.R. Role of the immunological environment in cancer initiation, development and progression. In: "The Tumor Immunoenvironment", M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp.1-12, 2013.
  • Shurin M.R., Umansky V. Chemoimmunomodulation: Focus on myeloid regulatory cells. In: "The Tumor Immunoenvironment", M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp. 603-619, 2013.
  • Malyguine A., Dunham K., Sayers T., Shurin M.R. Evaluation of the tumor immunoenvironment in clinical trials. In: "The Tumor Immunoenvironment", M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp. 695-706, 2013.
  • Zhu P., Segal Y.V., Shurin G.V., Shurin M.R. Analysis of myeloid-derived suppressor cells in patients with cancer. In: "The Tumor Immunoenvironment", M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp.707-723, 2013.
  • Shurin G.V., Ma Y., Shurin M.R. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenvironment, 2013, in press.


  • "The Tumor ImmunoEnvironment", M.R.Shurin, V.Umansky, A.Malyguine (Eds), 745 pages. Springer Publ., N.Y., 2013. (ISBN 978-94-007-6216-6)